Triple Drug Combination significantly lowers LDL C in dyslipedemia patients: Study

Key findings of the study:

• At 6 weeks, the researchers noted that the triple therapy group had a mean LDL reduction of –63.6% compared with –3.1% among patients treated with placebo.
• They also observed a significant reduction for non–high-density lipoprotein cholesterol, total cholesterol, apolipoprotein B, and high-sensitivity C-reactive protein with triple therapy when compared with placebo.
• At 6 weeks, in the triple therapy group, they found that 90% of patients achieved LDL of less than 70 mg/dL and, 95% of patients had LDL lowered by at least 50%. However, they did not observe this achievement with a placebo.
• They noted that the majority of treatment-emergent adverse events were mild to moderate in severity with no events of elevations in aminotransferase or creatine kinase levels.

The authors concluded, " Among patients with hypercholesterolemia, the combination of bempedoic acid, ezetimibe, and atorvastatin significantly lowered LDL-C by 60.5% compared with placebo, allowing more than 90% of patients in this study to reach the recommended LDL-C <70 mg/dL goal."

For further information:

https://www.atherosclerosis-journal.com/article/S0021-9150(20)31597-5/fulltext